undamentalytics Newsletter
Sign in

Marker Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Marker Therapeutics, Inc. had total assets of $19.1m, total liabilities of $2.3m and shareholders' equity of $16.8m. It held $16.1m in cash against $0 of debt: net cash of $16.1m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMMar 2026
Cash and equivalents5624421421215191615
Total current assets5624524461717221917
Total assets5624646683417221917
Accounts payable1213511112
Deferred revenue (current)————10——1—
Total current liabilities23261383324
Total debt0000000000
Total liabilities2321824153324
Shareholders' equity4594427442014191714
Net debt (negative = net cash)−5−62−44−21−42−12−15−19−16−15
Shares outstanding————8m8m9m11m17m17m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: DBVT vs MRKRDYAI vs MRKRALGS vs MRKR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Marker Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Marker Therapeutics, Inc.